Two-Dose Hepatitis A Revaccination Schedule Optimal for Patients With HIV
Researchers evaluated the optimal timing for vasopressin initiation for reducing the risk of mortality among patients with septic shock.
Diagnosis & Disease Information
Injection Drug Use-Associated HIV, HCV Risk Higher in Women, Younger Individuals
Researchers evaluated global data on HIV infection and primary hepatic C virus infection incidence among injections drug users.
Point-of-Care HCV Testing Improves Treatment Uptake, Time to Initiation
Researchers compared hepatitis C virus point-of-care RNA viral load testing with laboratory-based testing to determine the effects on treatment uptake and turnaround times.
Managing Hepatitis C in Treatment-Naïve Patients With HIV Coinfection
Studies show that mortality, morbidity, and hepatic decompensation risks increase with coinfection of HIV and HCV, indicating that adequate and efficient treatment must be provided for both viruses.
Liver May Be Reservoir for HIV DNA in Patients With HBV Coinfection on ART
Researchers evaluated whether HIV DNA persists in the liver among individuals receiving suppressive antiretroviral therapy.
HIV Serostatus Affects Hepatitis C Virus Care Cascade
Researchers sought to evaluate differences in immunologic markers between those with HIV and those at risk for HIV with opioid use disorder.
HepB-CpG Vaccination Achieves Maximum Seroprotection in Patients With HIV
Researchers evaluated patients with HIV infection who received the HepB-CpG vaccine, a hepatitis B surface antigen vaccine adjuvanted with a toll-like receptor 9 agonist.
How Can Hepatitis Vaccination Adherence Be Improved for At-Risk Adults?
Adults at risk of hepatitis A and hepatitis B have multi-dose vaccinations available, but complete and timely vaccination adherence rates are low. What can be done to encourage more vaccine adherence?
Treatment for Hepatitis C Up Among People Who Inject Drugs
Among persons who inject drugs with chronic HCV infection, proportion with detectable HCV RNA decreased from 100% in 2006 to 48% in 2019.
No Increase Seen in Pediatric Hepatitis in the United States
No increase in acute hepatitis of unspecified etiology, adenovirus types 40/41 above prepandemic baseline levels.
- Loading...
Loading...
Next post in Hepatology Information Center
Loading... 
Loading...